Immunai

Consolidates heterogeneous immune datasets from multiple sources (transcriptomics, proteomics, TCR/BCR sequencing) into a unified analytical framework. Eliminates data silos by harmonizing different data modalities into a single coherent immune profile.

Automatically identifies and classifies immune cell types from multi-omic data using machine learning models trained on immune cell reference datasets. Assigns cell type labels and confidence scores to individual cells or cell populations.

Identifies biological pathways and molecular networks active in immune cells and populations. Maps signaling cascades, metabolic pathways, and regulatory networks underlying immune function.

Evaluates quality of multi-omic immune datasets and applies normalization and batch correction methods. Identifies and mitigates technical artifacts, batch effects, and data quality issues.

Builds predictive models of immune responses to stimuli, treatments, or disease states. Generates quantitative predictions of immune cell behavior and population changes.

Enables systematic comparison of immune characteristics across different diseases, disease stages, or patient subgroups. Identifies disease-specific immune signatures and cross-disease immune patterns.

Identifies previously uncharacterized or rare immune cell populations through unsupervised learning and pattern recognition across multi-omic datasets. Surfaces novel cell states and populations that may have therapeutic or diagnostic significance.

Generates comprehensive visualizations and quantitative summaries of immune cell composition and organization across multiple patient samples or disease states. Enables comparative analysis of immune landscapes between conditions.

Analyzes immune cell populations and their molecular features to identify mechanisms underlying disease pathogenesis. Correlates immune characteristics with disease phenotypes and clinical outcomes.

Identifies potential drug targets by analyzing immune cell populations, pathways, and molecular features associated with disease or treatment response. Prioritizes targets based on biological relevance and druggability.

Identifies immune cell populations, gene signatures, or protein markers predictive of disease state, treatment response, or clinical outcomes. Validates biomarkers across cohorts and generates quantitative scoring systems.

Analyzes T cell receptor and B cell receptor sequences to characterize adaptive immune repertoires, clonality, diversity, and antigen-specific responses. Identifies clonally expanded populations and tracks immune responses.

Characterizes functional states of immune cells including activation status, exhaustion markers, memory phenotypes, and metabolic states. Quantifies cell state transitions and identifies state-specific molecular signatures.

Analyzes interactions between immune cells and tumor cells within the tumor microenvironment. Characterizes immune infiltration patterns, immune-tumor cell interactions, and immunosuppressive mechanisms.